Cargando…
The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine
Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 12, is expressed in sites of injury, chronic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338432/ https://www.ncbi.nlm.nih.gov/pubmed/25708982 http://dx.doi.org/10.1038/srep08569 |
_version_ | 1782481213213114368 |
---|---|
author | Julier, Ziad Martino, Mikaël M. de Titta, Alexandre Jeanbart, Laura Hubbell, Jeffrey A. |
author_facet | Julier, Ziad Martino, Mikaël M. de Titta, Alexandre Jeanbart, Laura Hubbell, Jeffrey A. |
author_sort | Julier, Ziad |
collection | PubMed |
description | Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 12, is expressed in sites of injury, chronic inflammation, and solid tumors. Although its function is not well understood, FNIII EDA is known to agonize Toll-like receptor 4 (TLR4). Here, by producing various FN fragments containing FNIII EDA, we found that FNIII EDA's immunological activity depends upon its local intramolecular context within the FN chain. N-terminal extension of the isolated FNIII EDA with its neighboring FNIII repeats (FNIII 9-10-11) enhanced its activity in agonizing TLR4, while C-terminal extension with the native FNIII 12-13-14 heparin-binding domain abrogated it. In addition, we reveal that an elastase 2 cleavage site is present between FNIII EDA and FNIII 12. Activity of the C-terminally extended FNIII EDA could be restored after cleavage of the FNIII 12-13-14 domain by elastase 2. FN being naturally bound to the ECM, we immobilized FNIII EDA-containing FN fragments within a fibrin matrix model along with antigenic peptides. Such matrices were shown to stimulate cytotoxic CD8(+) T cell responses in two murine cancer models. |
format | Online Article Text |
id | pubmed-4338432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43384322015-03-04 The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine Julier, Ziad Martino, Mikaël M. de Titta, Alexandre Jeanbart, Laura Hubbell, Jeffrey A. Sci Rep Article Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 12, is expressed in sites of injury, chronic inflammation, and solid tumors. Although its function is not well understood, FNIII EDA is known to agonize Toll-like receptor 4 (TLR4). Here, by producing various FN fragments containing FNIII EDA, we found that FNIII EDA's immunological activity depends upon its local intramolecular context within the FN chain. N-terminal extension of the isolated FNIII EDA with its neighboring FNIII repeats (FNIII 9-10-11) enhanced its activity in agonizing TLR4, while C-terminal extension with the native FNIII 12-13-14 heparin-binding domain abrogated it. In addition, we reveal that an elastase 2 cleavage site is present between FNIII EDA and FNIII 12. Activity of the C-terminally extended FNIII EDA could be restored after cleavage of the FNIII 12-13-14 domain by elastase 2. FN being naturally bound to the ECM, we immobilized FNIII EDA-containing FN fragments within a fibrin matrix model along with antigenic peptides. Such matrices were shown to stimulate cytotoxic CD8(+) T cell responses in two murine cancer models. Nature Publishing Group 2015-02-24 /pmc/articles/PMC4338432/ /pubmed/25708982 http://dx.doi.org/10.1038/srep08569 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Julier, Ziad Martino, Mikaël M. de Titta, Alexandre Jeanbart, Laura Hubbell, Jeffrey A. The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine |
title | The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine |
title_full | The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine |
title_fullStr | The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine |
title_full_unstemmed | The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine |
title_short | The TLR4 Agonist Fibronectin Extra Domain A is Cryptic, Exposed by Elastase-2; use in a fibrin matrix cancer vaccine |
title_sort | tlr4 agonist fibronectin extra domain a is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338432/ https://www.ncbi.nlm.nih.gov/pubmed/25708982 http://dx.doi.org/10.1038/srep08569 |
work_keys_str_mv | AT julierziad thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT martinomikaelm thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT detittaalexandre thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT jeanbartlaura thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT hubbelljeffreya thetlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT julierziad tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT martinomikaelm tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT detittaalexandre tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT jeanbartlaura tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine AT hubbelljeffreya tlr4agonistfibronectinextradomainaiscrypticexposedbyelastase2useinafibrinmatrixcancervaccine |